Innovative Clinical Trials: The LUNG-MAP Study

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 5, 2015, Pages 488-491

  Steuer, C E ^a   Papadimitrakopoulou, V ^b   Herbst, R S ^c   Redman, M W ^d   Hirsch, F R ^e   Mack, P C ^f   Ramalingam, S S ^a   Gandara, D R ^f  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c YALE CANCER CENTER   (United States)

^d SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HUMAN; LUNG NEOPLASMS; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROCEDURES; SECONDARY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PHENOTYPE; PRECISION MEDICINE; RESEARCH DESIGN; SIGNAL TRANSDUCTION;

EID: 84965086826     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/CPT.88     Document Type: Article

References (22)

1. Solomon, B.J. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371, 2167–2177 (2014).
2. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239–246 (2012).
3. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11–30 (2013).
4. Network CGAR. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 489, 519–525 (2012).
5. Menis, J., Hasan, B. & Besse, B. New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. Eur. Respir. Rev. 23, 367–378 (2014).
6. Kim, E.S. et al. The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov. 1, 44–53 (2011).
7. Champiat, S. et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J. Thorac. Oncol. 9, 144–153 (2014).
8. Ramalingam, S.S. et al. Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer: metastatic non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 90, 1266–1267 (2014).
9. Garon, E. et al. Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). ESMO. Barcelona, Spain.
10. Segal, N. et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. Chicago: ASCO.
11. Samuels, Y. & Velculescu, V.E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 3, 1221–1224 (2004).
12. Massion, P.P. et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am. J. Respir. Crit. Care Med. 170, 1088–1094 (2004).
13. Ndubaku, C.O. et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyra-zol-1-yl}-2-methylpropanamide (GDC-0032): A beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J. Med. Chem. 56, 4597–4610 (2013).
14. Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770–1783 (2006).
15. Finn, R.S. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 16, 25–35 (2015).
16. Dickson, M.A. et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J. Clin. Oncol. 31, 2024–2028 (2013).
17. Gavine, P.R. et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72, 2045–2056 (2012).
18. Zhang, J. et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin. Cancer Res. 18, 6658–6667 (2012).
19. Paik, P. et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data. Clin Oncol 32, 5s, (2014).
20. Ma, P.C. et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65, 1479–1488 (2005).
21. Guo, A. et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. U. S. A. 105, 692–697 (2008).
22. Richey, E.A. et al. Accelerated approval of cancer drugs: Improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs, J. Clin. Oncol. 27, 4398–4405 (2009).